

Plant Bioscience Limited and Large Scale Biology Announce an Exclusive Licensing Agreement in Plant Functional Genomics

VACAVILLE, California, June 20, 2001 - Large Scale Biology Corporation and Plant Bioscience Limited (PBL), Norwich, UK, announced today a broad, exclusive licensing and option agreement in plant functional genomics that will enable a major expansion of LSBC's high-throughput, gene discovery capabilities by combining LSBC's proprietary GENEWARE[®] genomics platform with PBL's substantial portfolio of technologies in this field. Under the terms of the agreement, PBL is granting an exclusive license to certain viral-derived gene silencing and overexpression technologies developed by Professor David Baulcombe and colleagues at The Sainsbury Laboratory, Norwich, UK. PBL is also granting an exclusive license to certain other viral-derived technologies for gene silencing and enhanced gene expression developed at North Carolina State University (by Professor Niki Robertson) and the University of South Carolina (by Professor Vicki Vance) and exclusively licensed to PBL.

"Our GENEWARE functional genomics technology allows us rapidly to determine the function of completely uncharacterised gene sequences via high-throughput robotic cloning and transfection of mature plants. With this expanded portfolio of gene silencing and overexpression capabilities from PBL, we aim to be the definitive provider of genes and technologies for manipulating metabolic pathways in plants to lead to new routes for production of high performance chemicals, nutraceuticals, pharmaceutical intermediates, and improved agricultural crops and products," said Dr Guy della-Cioppa, Vice President of Business Development for LSBC.

"We see many commercial applications for our technology in agricultural markets and expect this alliance with PBL to accelerate our ability to successfully address many new opportunities. After the past three years of outstanding success in agricultural genomics which has resulted in cash payments to the company in excess of \$45 million, we are in a position to be much more aggressive in our agriculture business," said Robert Erwin, Chairman and CEO of LSBC.

"We are excited that this interaction will combine two exceptionally strong technology packages, providing a full platform of state-of-the-art options for all aspects of plant functional genomics, and viral-based manufacture of valuable compounds in plants. Large Scale is a natural choice of partner to deliver our plant functional genomics technology to a wider customer base," said PBL's Managing Director, Dr Jan Chojecki.

About Large Scale Biology Corporation

Large Scale Biology uses its proteomics, functional genomics and biomanufacturing technologies to develop and manufacture personalized drugs, vaccines and diagnostics for rapid identification and effective treatment of disease. Corporate offices and the Genomics and Antigenics divisions are headquartered in Vacaville, California; the Company's Proteomics subsidiary is located in Germantown, Maryland; and the Company's bioprocessing and manufacturing facilities are located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbcc.com.